Results 171 to 180 of about 2,061,103 (249)

The established electrocardiographic classification of anterior wall myocardial infarction misguides clinicians in terms of infarct location, extent and prognosis. [PDF]

Ann Noninvasive Electrocardiol, 2019
Bozbeyoğlu E, Aslanger E, Yıldırımtürk Ö, Şimşek B, Hünük B, Karabay CY, Kozan Ö, Değertekin M.   +7 more
europepmc   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

The "Spiked Helmet Sign" on Electrocardiogram Following Left Ventricular Assist Device Implantation: A Case Report. [PDF]

Ann Noninvasive Electrocardiol
The Spiked Helmet Sign on electrocardiogram after LVAD implantation serves as a critical early warning of localized pericardial hematoma and impending tamponade. Prompt recognition should trigger immediate echocardiographic evaluation, as demonstrated in this case, to guide urgent management.
Qian Q, Yin L.
europepmc   +2 more sources

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Association of altered body composition with cardiac wasting in cancer with and without cardiotoxic therapy

British Journal of Pharmacology, EarlyView.
Created in BioRender: Scientific Figure and Illustration Software. Background and Purpose In advanced cancer, associations among changes in body composition, cardiac wasting and prior cardiotoxic anticancer therapy have not been investigated. Experimental Approach Using bioelectrical impedance analysis (BIA), body composition was measured in 206 ...
Sara Hadzibegovic, Jonathan L. Hella, Jan Porthun, Alessia Lena, Danara Krug, Iulia Baluta, Ursula Wilkenshoff, Amir A. Mahabadi, Matthias Totzeck, Tienush Rassaf, Stefan D. Anker, Wolfram Doehner, Ulrich Keller, Lars Bullinger, Dominik P. Modest, Barry J. A. Laird, Richard J. E. Skipworth, John G. F. Cleland, Christian Oeing, Stephan von Haehling, Ulf Landmesser, Markus S. Anker   +21 more
wiley   +1 more source

Targeted delivery of the CB2 receptor agonist JWH‐133 via VCAM‐1‐functionalised nanoparticles attenuates atherosclerosis and reveals sex‐specific therapeutic outcomes

British Journal of Pharmacology, EarlyView.
Background and Purpose Atherosclerosis, a chronic inflammatory disease characterised by lipid accumulation and endothelial dysfunction, remains a leading cause of cardiovascular morbidity and mortality. While cannabinoid 2 (CB2) receptor agonists show therapeutic promise in preclinical studies, their systemic application is hindered by poor ...
Lucía Martín‐Navarro, Lucía Martín‐Banderas, Josefa Álvarez‐Fuentes, María Dolores Herrera‐González   +3 more
wiley   +1 more source

Delayed ventricular septal rupture complicating anterior wall myocardial infarction. [PDF]

BMJ Case Rep, 2016
Dulai R, Hline A, Javaid MR, Akhtar J.
europepmc   +1 more source

Kininase I drives angiotensin II‐induced hypertension through activation of the bradykinin B1 receptor

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Kininase I, comprising carboxypeptidase N (CPN) and carboxypeptidase M, regulates kinin activity and is up‐regulated during injury, inflammation and immune activation. Under these conditions, kininase I converts bradykinin and kallidin into des‐Arg kinins, primary endogenous agonists of the bradykinin B1 receptor (R ...
Acacia White, Drew Theobald, Alexandra Johnston, David A. Tulis, Johanna Hannan, Srinivas Sriramula   +5 more
wiley   +1 more source